CRISPR Therapeutics AG
NASDAQ:CRSP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
44.62
89.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
CRISPR Therapeutics AG
Wall Street
Price Targets
CRSP Price Targets Summary
CRISPR Therapeutics AG
According to Wall Street analysts, the average 1-year price target for
CRSP
is 81.43 USD
with a low forecast of 30.3 USD and a high forecast of 208.95 USD.
CRSP Last Price Targets
CRISPR Therapeutics AG
The latest public price target was made on Nov 6, 2024 by
Jay Olson
from
Oppenheimer
,
who expects
CRSP
stock to
rise by 93%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jay Olson
Oppenheimer
|
95
USD
Upside 93% |
3 weeks ago
Nov 6, 2024
|
Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)
StreetInsider
|
|
Rick Bienkowski
Leerink Partners
|
67
USD
Upside 36% |
3 weeks ago
Nov 5, 2024
|
CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners
StreetInsider
|
Joon Lee
Truist Financial
|
100
USD
Upside 103% |
3 months ago
Aug 12, 2024
|
Crispr Therapeutics price target lowered to $100 from $120 at Truist
TheFly
|
Gil Blum
Needham
|
84
USD
Upside 70% |
3 months ago
Aug 6, 2024
|
CRISPR Therapeutics (CRSP) PT Lowered to $84 at Needham
StreetInsider
|
Luca Issi
RBC Capital
|
60
USD
Upside 22% |
3 months ago
Aug 6, 2024
|
CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
StreetInsider
|
Benjamin Burnett
Stifel Nicolaus
|
59
USD
Upside 20% |
3 months ago
Aug 6, 2024
|
CRISPR Therapeutics (CRSP) PT Lowered to $59 at Stifel
StreetInsider
|
Jack Allen
Robert W. Baird
|
52
USD
Upside 5% |
6 months ago
May 9, 2024
|
CRISPR Therapeutics (CRSP) PT Raised to $52 at Baird
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CRSP's stock price target?
Price Target
81.43
USD
According to Wall Street analysts, the average 1-year price target for
CRSP
is 81.43 USD
with a low forecast of 30.3 USD and a high forecast of 208.95 USD.
What is CRISPR Therapeutics AG's Revenue forecast?
Projected CAGR
28%
For the last 8 years the
compound annual growth rate for
CRISPR Therapeutics AG's revenue is
156%.
The projected
CAGR
for the next 3 years is
28%.
You don't have any saved screeners yet
